<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> disease in which unique subtypes are characterized by distinct genetic and epigenetic alterations </plain></SENT>
<SENT sid="1" pm="."><plain>Here we performed comprehensive genome-scale DNA methylation profiling of 125 colorectal <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and 29 adjacent <z:mpath ids='MPATH_458'>normal</z:mpath> tissues </plain></SENT>
<SENT sid="2" pm="."><plain>We identified four DNA methylation-based subgroups of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> using model-based cluster analyses </plain></SENT>
<SENT sid="3" pm="."><plain>Each subtype shows characteristic genetic and clinical features, indicating that they represent biologically distinct subgroups </plain></SENT>
<SENT sid="4" pm="."><plain>A CIMP-high (CIMP-H) subgroup, which exhibits an exceptionally high frequency of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific DNA hypermethylation, is strongly associated with MLH1 DNA hypermethylation and the BRAF(V600E) mutation </plain></SENT>
<SENT sid="5" pm="."><plain>A CIMP-low (CIMP-L) subgroup is enriched for KRAS mutations and characterized by DNA hypermethylation of a subset of CIMP-H-associated markers rather than a unique group of CpG islands </plain></SENT>
<SENT sid="6" pm="."><plain>Non-CIMP <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> are separated into two distinct clusters </plain></SENT>
<SENT sid="7" pm="."><plain>One non-CIMP subgroup is distinguished by a significantly higher frequency of TP53 mutations and frequent occurrence in the distal colon, while the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> that belong to the fourth group exhibit a low frequency of both <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific DNA hypermethylation and gene mutations and are significantly enriched for <z:e sem="disease" ids="C1527408,C0034885" disease_type="Disease or Syndrome;Neoplastic Process" abbrv="">rectal tumors</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, we identified 112 genes that were down-regulated more than twofold in CIMP-H <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> together with promoter DNA hypermethylation </plain></SENT>
<SENT sid="9" pm="."><plain>These represent âˆ¼7% of genes that acquired promoter DNA methylation in CIMP-H <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Intriguingly, 48/112 genes were also transcriptionally down-regulated in non-CIMP subgroups, but this was not attributable to promoter DNA hypermethylation </plain></SENT>
<SENT sid="11" pm="."><plain>Together, we identified four distinct DNA methylation subgroups of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and provided novel insight regarding the role of CIMP-specific DNA hypermethylation in gene silencing </plain></SENT>
</text></document>